Health Care Distributors

GUANGXI LIUYAO GROUP

GUANGXI LIUYAO GROUP released FY2026 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 5.377 B, actual EPS CNY 0.64

GUANGXI LIUYAO GROUP released FY2025 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 5.168 B, actual EPS CNY 0.1605

GUANGXI LIUYAO GROUP released FY2025 earnings on April 29 After-Market (BJT), actual revenue CNY 20.93 B (forecast CNY 21.17 B), actual EPS CNY 1.79 (forecast CNY 1.94)

GUANGXI LIUYAO GROUP to Release FY2025 Earnings on April 30 After-Market (BJT), Forecast Revenue CNY 21.17 B, EPS CNY 1.94

GUANGXI LIUYAO GROUP to Release FY2026 Q1 Earnings on April 30, Pre-Market BJT

GUANGXI LIUYAO GROUP released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 5.457 B, actual EPS CNY 0.55

GUANGXI LIUYAO GROUP released FY2025 9 Months earnings on October 29 During-Market (BJT), actual revenue CNY 15.76 B, actual EPS CNY 1.6311

GUANGXI LIUYAO GROUP FY2025 Q3 Earnings Release on October 30, 2025 During-Market (BJT)

GUANGXI LIUYAO GROUP released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), actual revenue CNY 10.3 B, actual EPS CNY 1.08

GUANGXI LIUYAO GROUP released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 4.984 B, actual EPS CNY 0.381

GUANGXI LIUYAO GROUP to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

GUANGXI LIUYAO GROUP released FY2025 Q1 earnings on April 28 Pre-Market BJT, actual revenue CNY 5.317 B, actual EPS CNY 0.7

GUANGXI LIUYAO GROUP to Release FY2025 Q1 Earnings Report on April 29 Pre-Market BJT

GUANGXI LIUYAO GROUP released FY2024 annual earnings on March 26 After-Market (BJT), actual revenue 21.18 B CNY (forecast 22.33 B CNY), actual EPS 2.21 CNY (forecast 2.405 CNY)

GUANGXI LIUYAO GROUP released FY2024 Q4 earnings on March 26 After-Market (BJT), actual revenue 5.189 B CNY, actual EPS 0.3484 CNY

GUANGXI LIUYAO GROUP to Release FY2024 Earnings on March 27 After-Market (BJT), Forecast Revenue 22.33 B CNY, EPS 2.405 CNY

GUANGXI LIUYAO GROUP released FY2024 Q3 earnings on October 29 After-Market (BJT), with actual revenue of 53.51 亿 CNY and EPS of 0.6295 CNY

GUANGXI LIUYAO GROUP released FY2024 9 Months Earnings on October 29 After-Market (BJT), with actual revenue of 15.99 B CNY and EPS of 1.8831 CNY

Guangxi LiuYao Group Co., Ltd to Announce Q3 2024 Earnings on October 30, 2024

Liu Medicine Group releases performance briefing announcement

09988

513060

512290

603368

According to the Hong Kong Stock Connect data, the net inflow from northbound to southbound was HKD 935 million for CSPC PHARMA, HKD 914 million for Xiaomi Corporation, and HKD 330 million for Alibaba. In terms of net outflows, Zijin Mining saw HKD 635 million, CNOOC HKD 526 million, and Tencent HKD 213 million. The highest net inflow for the Hong Kong Stock Connect (Shanghai) was HKD 692 million for CSPC PHARMA, while the highest net outflow was HKD 921 million for CNOOC. The total net outflow for the day was HKD 0, with a total transaction amount of HKD 116.489 billion, accounting for 38.62% of the total market transaction amount

AASTOCKS

BABA-W

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

GF Fund CSI HK Connect Financials(ex Banks) Thematic ETF

KraneShares 2x Long BABA Daily ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ALI HEALTH

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI HK Connect Internet ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao CSI HK Equities Internet ETF

ChinaAMC CSI Biotechnology Theme ETF

CSPC PHARMA

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Xiaomi Corporation

GF CSI HK Innovative Drugs Industry ETF(QDII)

Alibaba

Yinhua CSI Innovative Drugs Industry ETF

BABA 2x Long Daily ETF - GraniteShares

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Financials (ex Banks) ETF

Hwabao WP CSI Pharmaceuticals ETF

XIAOMI-W

TENCENT

Net inflow of CSPC PHARMA through Hong Kong Stock Connect is HKD 935 million

As of October 31, 2025, GUANGXI LIUYAO GROUP repurchased 9.7746 million shares through centralized bidding transactions, accounting for 2.46% of the total share capital. The repurchase amount was 180 million yuan, with a highest transaction price of 19.07 yuan/share and a lowest of 17.83 yuan/share

Zhitong

GUANGXI LIUYAO GROUP has repurchased a total of 9.7746 million shares at a cost of 180 million yuan

605365

605196

300157

On September 25th, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 40.982 million yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares New JCM 300157 Equity Incentive Restricted Circulation 6.7375 million GUANGXI LIUYAO GROUP 603368 Equity Incentive Restricted Circulation 784,200 HUATONG WIRES & CABLES GROUP 605196 Equity Incentive Restricted Circulation 30,000 Leedarson IoT 605365 Equity Incentive Restricted Circulation 247,100

Leedarson IoT

HUATONG WIRES & CABLES GROUP

NEW JCM

Zhitong A-share lock-up release overview | September 25

HUAWEI

According to news from GUANGXI LIUYAO GROUP, recently, GUANGXI LIUYAO GROUP held a high-level exchange seminar with Huawei Technologies Co., Ltd. Both parties conducted in-depth discussions on topics such as the digital transformation of the pharmaceutical industry, the application of artificial intelligence, and supply chain optimization, aiming to further promote the implementation of strategic cooperation and jointly create a new benchmark for smart medicine

Huawei

GUANGXI LIUYAO GROUP held a high-level exchange seminar with Huawei to explore cooperation in pharmaceutical intelligence

GUANGXI LIUYAO GROUP announced that as of September 8, 2025, the company has repurchased a total of 8.1079 million shares through centralized bidding, accounting for 2.04% of the company's current total share capital, an increase of 0.76% compared to the last repurchase progress announcement. The highest transaction price for the repurchase was 18.6 yuan/share, and the lowest price was 17.83 yuan/share, with a total amount paid of 148 million yuan. The estimated amount for this repurchase is between 100 million and 200 million yuan, intended for the employee stock ownership plan or equity incentives

GUANGXI LIUYAO GROUP: The cumulative repurchased shares account for 2.04% of the total share capital

According to the Zhitong Finance APP, GUANGXI LIUYAO GROUP announced that the company plans to repurchase shares worth 100 million to 200 million yuan, with the repurchase price not exceeding 25.70 yuan per share. The repurchased shares are intended to be used for implementing equity incentives and/or employee stock ownership plans at an appropriate time in the future; if the company fails to implement the aforementioned purposes within three years after the completion of this share repurchase, the unused repurchased shares will undergo the relevant procedures for cancellation

GUANGXI LIUYAO GROUP plans to repurchase shares worth 100 million to 200 million yuan

GUANGXI LIUYAO GROUP released its 2024 annual report, with operating revenue of 21.182 billion yuan, a year-on-year increase of 1.78%; net profit attributable to the parent company was 855 million yuan, a year-on-year increase of 0.62%. The net profit excluding non-recurring gains and losses was 837 million yuan, a year-on-year decrease of 0.01%. Basic earnings per share were 2.21 yuan, and it is proposed to distribute a cash dividend of 7.51 yuan for every 10 shares. The company continues to promote product research and development and market expansion in the pharmaceutical industry sector, maintaining steady growth

GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%

According to the Qichacha APP, recently, Guangxi Liuyao Yusheng Medical Equipment Co., Ltd. was established, with Qin Zhaoyou as the legal representative and a registered capital of 5 million yuan. The business scope includes: operation of Class III medical devices; wholesale of protective equipment for medical personnel; retail of protective equipment for medical personnel; food sales; sales of health food, etc. Qichacha's equity penetration shows that the company is wholly owned by LIUYAO GROUP indirectly

Ligao Foods

CHOW TAI FOOK

YONGAN PHARMACEUTICAL

GUOLIAN AQUATIC

MSJK

Kingdomway

GUOQUAN

GUANGDONG GUANGHONG HOLDINGS

ZHENDE MEDICAL

Shouxiangu

TOPSPORTS

GUANGXI LIUYAO GROUP established a medical device company that includes health food sales business

GUANGXI LIUYAO GROUP(603368.SH)